A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 17 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Events
  • Conference: World AMR Congress 2021: Biotechs are saving...
Conference - Event date: 09 Nov 2021
Share

World AMR Congress 2021: Biotechs are saving the world from superbugs. Can they also save themselves?

On Tuesday 9 November 2021, Fatema Rafiqi, Programme Manager for the Antimicrobial Resistance Benchmark, will join the 2021 World AMR Congress in Washington, DC. 

Explore further

News

What are pharma companies doing to slow the superbugs? New report out soon.

Superbugs threaten to cause the next pandemic. On Thursday 18 November, the Access to Medicine Foundation will publish the 2021 Antimicrobial Resistance Benchmark, which will provide the latest deep dive into whether pharmaceutical companies are doing enough to curb drug resistance.
News

Biotech’s antibiotic warriors need new reward system in superbug fight

Today, a new report by the Foundation examines how small drugmakers, which are pivotal in antibiotic development, are navigating the tough market. It identifies a small crop of biotechs that are finding new ways to survive and bring their life-saving meds to patients. With better incentives, this could lead to global access.

Get in touch

Back to top |